According to Karyopharm Therapeutics 's latest financial reports the company's current revenue (TTM) is $0.14 B. In 2022 the company made a revenue of $0.15 B a decrease over the years 2021 revenue that were of $0.20 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.14 B | -7.03% |
2022 | $0.15 B | -25.14% |
2021 | $0.20 B | 94.12% |
2020 | $0.10 B | 164.31% |
2019 | $40.89 M | 34.8% |
2018 | $30.33 M | 1790.09% |
2017 | $1.6 M | 942.21% |
2016 | $0.15 M | -38.4% |
2015 | $0.25 M | 9.65% |
2014 | $0.22 M | -41.09% |
2013 | $0.38 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Abbott Laboratories ABT | $40.10 B | 27,365.71% | ๐บ๐ธ USA |
Merck MRK | $60.11 B | 41,064.67% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.53 B | 31,080.62% | ๐บ๐ธ USA |
Exelixis EXEL | $1.83 B | 1,153.28% | ๐บ๐ธ USA |